Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to ...

Eli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Investors might want to bet on Verve Therapeutics (VERV), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Analysts are raising their ratings and price targets on Verve Therapeutics stock today. Verve published very encouraging trial data for its VERVE-102 treatment yesterday. Investors think that the ...

Verve Therapeutics is at the forefront of a new wave of gene editing therapies aimed at tackling cardiovascular diseases, which remain a leading cause of death worldwide. The company’s primary ...

Verve Therapeutics (NASDAQ:VERV – Free Report) had its price objective increased by Guggenheim from $18.00 to $24.00 in a research report sent to investors on Tuesday morning, Marketbeat reports.

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.